Company profile
UK company NI619901, incorporated on 16 August 2013.
Home - ProAxsis
ProAxsis develops and supplies diagnostic assays focusing on biomarkers that aid clinical intervention which leads to improved patient outcomes.
Company number NI619901
Reference milestones and recent Companies House filing stream events.
SH01 | Transaction MzU0MzM0OTQzMGFkaXF6a2N4
Published 08 Sep 2026 17:00
CS01 | Transaction MzU0MTA3NTg5MGFkaXF6a2N4
Published 26 Aug 2026 16:55
SH01 | Transaction MzUzOTcyNDgxMWFkaXF6a2N4
Published 19 Aug 2026 11:42
SH01 | Transaction MzUzOTcyNTU4M2FkaXF6a2N4
Published 19 Aug 2026 11:27
MA | Transaction MzUzNzk4MjcyMmFkaXF6a2N4 | Paper/PDF filed
Published 14 Aug 2026 22:52
SH02 | Transaction MzUzNzk4MjcyMGFkaXF6a2N4 | Paper/PDF filed
Published 14 Aug 2026 22:52
Company registered at Companies House
The work carried out in Dr Martin's CiC project in 2012, also attracted the early attention of AIM listed NetScientific plc, a healthcare medical technology company that commercialises research and technologies originating from leading universities. Working in partnership with NetScientific accelerated the formation of a new University spin-out venture called ProAxsis Ltd. The company has secured a range of investors including venture funding alongside Netscientific and others.
ProAxsis is an in vitro diagnostics company in Northern Ireland that focuses on respiratory diagnostic assays to aid clinical intervention and improve patient outcomes.
ProAxsis has developed a range of tools to detect and monitor chronic diseases including cystic fibrosis and chronic obstructive pulmonary disease.
ProAxsis was named as one of Northern Ireland's most promising technology companies, winning the annual NISP Connect 25K awards in 2013 and recently secured funding from the first round of EU Horizon 2020 funding for small businesses. By 2018, the key technology licenced into the company from the original funded project had achieved CE mark status. In addition, the company's ProteaseTag® Active NE Immunoassay, and NEATstik®, the first test to enable measurement of active neutrophil elastase at point-of-care, have been selected for inclusion in a major upcoming clinical trial. The BRIDGE study is a 3-year collaborative study, funded by the European Respiratory Society (ERS), in which 1000 patients with bronchiectasis across Europe will be recruited and will have multiple assessments including microbiome, proteomics, detailed phenotyping and imaging. The study will explore novel biomarkers and demonstrate what they can add to clinical practice.
1 Nov 2024 to 31 Oct 2029
**The Northern Ireland Precision Biomarkers and Therapeutics Consortium (NIPBT)** is a partnership of Life and Health Science (LHS) companies and Academia, aligned to the strategies of both the Departments of Health and Economy of the NI devolved government to enhance health and wealth creation for NI citizens. Currently, NI has a significant presence in ...
1 Apr 2024 to 31 Dec 2025
The enzyme Neutrophil Elastase (NE) is associated with the severity of several respiratory diseases, including Chronic Obstructive Pulmonary Disease (COPD), where repeated cycles of infection and inflammation leads to active NE release from immune cells, causing lung damage. Active NE is predictive of lung function loss and is the most informative biomark...
1 Aug 2022 to 31 Jan 2025
1 Oct 2021 to 31 Dec 2022
The formation of blood clots has been identified as a potential risk factor for a very small proportion of individuals receiving certain types of COVID-19 vaccine. A larger proportion of people who have tested positive for COVID-19 (the infectious disease caused by the coronavirus) have also experienced inappropriate blood clotting, which has resulted in ...
1 Sep 2020 to 30 Nov 2021
ProAxsis is a Northern Ireland-based company which specialises in the measurement of a group of enzymes called proteases. Current tests being developed to support the fight against COVID-19 (the infectious disease caused by coronavirus) are focused on identifying patients who currently have, or have previously had, the virus. Whilst this is clearly useful...
1 Jun 2020 to 28 Feb 2021
There are a number of markers of inflammation which have been associated with various diseases. One group of such markers is the cytokines which are small proteins released by different cells in the body. These cytokines work as messengers and help co-ordinate the body's fight against infection and inflammation. Cytokines are often measured in the blood o...
1 Jul 2017 to 31 Mar 2018
Neutrophil Elastase (NE) activity is associated with the severity of respiratory diseases including Cystic Fibrosis (CF) Chronic Obstructive Pulmonary Disease (COPD) and bronchiectasis. In these diseases repeated cycles of infection and inflammation result in the release of NE which causes lung damage. NE is predictive of loss of lung function and is the ...
1 Feb 2017 to 31 Jan 2018
Pancreatic Insufficiency (PI) is a condition that occurs in a range of diseases including chronic pancreatitis, pancreatic cancer, diabetes, cystic fibrosis and inflammatory bowel disorders. Often, diagnosis is delayed as symptoms don't appear until almost all of the pancreatic function is lost. Pancreatic Elastase (PE), one of the enzymes normally releas...
